Review article: Current status and future directions of ingestible electronic devices in gastroenterology
INTRODUCTION Ingestible electronic microsystems containing sensors that can capture and transmit an array of biological data telemetrically, and/or deliver interventional functions represent a burgeoning area of science. These ingestible electronic microsystems can also contain sampling and drug‐release components. Until recently, the research and development for commercialisation of these ingestible devices have been tempered by technological challenges related to power supply, biocompatibility, device miniaturisation and the full demonstration of clinical relevance and economic viability. Considerable advances in many of these areas in recent times have enabled the design of a number of devices with screening, therapeutic and diagnostic capabilities. Altogether, such technologies have the potential to greatly alter historic paradigms of healthcare assessment and delivery, introducing a new era of personalised, digital medicine, especially in the field of gastroenterology. Ingestible devices are attractive tools for the inspection and assessment of the gastrointestinal tract due to its extended length and relative inaccessibility, allowing longitudinal analysis in real‐time, in an ambulatory setting and possibly with minimal patient inconvenience. Understanding the complex interplay between microbiome, host and dietary substrate and the locoregional variation of structure and function of the gastrointestinal tract is pivotal in the correct interpretation of gastrointestinal tract physiology in health and disease. Ingestible devices are likely to play an increasing role in this regard. There are a myriad of new devices in the pipeline. In light of the limited awareness of this rapidly expanding field, which is likely to infiltrate many areas of clinical practice in the not‐too‐distant future, the current narrative review aims to provide a comprehensive overview for the clinician, by exploring the key components of ingestible electronic devices and introducing some of the novel devices in the research and development or commercial pipeline. It will also explore the current challenges associated with the introduction of this technology into clinical practice and its future directions. 

METHODOLOGY In order to perform this narrative review, published literature, including those in abstract form, were systematically searched using PubMed, ProQuest, OVID and Google Scholar using keywords, that included ingestible, electronic devices, telemetric devices, capsules and sensors. Each subsection was additionally explored using targeted searching, for example, ‘ingestible electronic device AND microbiome’. Abstracts were appraised and relevant articles were then reviewed. Additional studies were located via cross‐referencing and via searching news reports/press releases and websites of technology companies. Studies in paediatric cohorts were not included. 

A PRIMER FOR WHAT IS REQUIRED TO CREATE AN INGESTIBLE ELECTRONIC DEVICE A description of components is needed to enable an understanding of issues such as the device's capabilities, risk, cost and privacy. Typical components are illustrated in Figure . Sensors and imaging tools : These have been designed to interact with the luminal microenvironment and measure biological information. Various sensors exist, including optical (camera), thermal, pH, pressure, semiconducting, fluorescence, spectrometric, electrochemical, acoustic and sonographic electronic conversion tools, which ultimately define the function of the device and is a major determinant of the device's battery requirements. Power source : The ingestible device requires a power source, which may be battery operated, or more recently, battery‐free. The capacity of the power source must be high enough to meet the needs of the microelectronic circuit and specific sensors and allow for sufficient operational time to complete the intended test. In battery‐operated devices, important considerations include the type of battery used, the amount of heat it generates as well as its size, the latter of which dictates the ingestible device's overall size. For example, silver oxide batteries are small and do not produce excessive current during short‐circuiting, but have a low power‐to‐weight ratio. In comparison, lithium batteries have better performance, but generate heat and carry the risk of thermal runaway, a faulty cycle catalysed by increased temperature that risks battery combustion. , Non‐battery sources of power, such as electromagnetic, piezoelectric (using kinetic energy) and triboelectric (using friction) have also been investigated in capsules and recently, there has been a focus on the development of biofuel cells, which generate energy via enzymatic or microbe‐related biochemical reactions. , Biofuel cells, such as the glucose biofuel cell, are biocompatible and do not generate much heat, but are expensive and their use has been limited by short lifespan, low power output and technological inconsistencies. Power switch : In order to conserve battery life, a switch is required to activate the electronic device prior to ingestion. This is often a magnetic switch, known as a reed switch. Microcontroller and data processor unit : Microcontrollers are crucial for all operational aspects of ingestible devices, including how and when to drive sensors and read the sensor output signals, storing and manipulating raw data for further interpretation and transmission and triggering mechanical events of the device such as opening cavities for therapeutic drug delivery or sampling. Data collection and transmission : A data receiver with a receiving antenna system and battery pack allows the data to be received from the electronic device. Wide bandwidth telecommunication is essential to allow this data transmission to occur. For example, 433 MHz is a common frequency used by biological devices. , Bluetooth® is an alternative way in which data may be transferred. Of critical importance, data transferred must be protected to ensure patient privacy. If the transfer of data is not possible, such as when samples or other data are collected and stored within the device, such as with CapsoCam Plus capsule endoscopy, the data may be retrieved upon collection of the device post‐excretion. , Capsule housing (cladding) : The individual components of the device are housed in an inert, biocompatible, pill‐shaped cladding resistant to damage from intestinal secretions (such as acid and enzymes) and microbial actions. Its size and shape are ultimately dictated by the components within, but ideally should be of a size amenable to swallowing and with minimal risk of retention. A typical size is less than 13 mm diameter and 34 mm length. A semipermeable membrane may be present to allow interaction between the sensor component and the lumen or to allow sampling to occur. Workstation with software program : Data obtained may be reviewed in real‐time or upon completion of the study. Dedicated software will allow data reporting and may include an automated computer‐generated reporting option. Devices may capture several hours of data for review, and computer‐assisted reviewing algorithms may be present to reduce viewing times and assist diagnosis. These may use artificial intelligence and machine learning (e.g. convolutional neural network, decision trees or clustering algorithms). 

MOVING THE CAPSULE THROUGH THE GASTROINTESTINAL TRACT Movement of the device through the gastrointestinal tract may be uncontrolled, or passive, or controlled through active manipulation. Similarly, movement can be inhibited. Passive locomotion is influenced by gravity and peristalsis of the bowel, which is variable and relatively unpredictable. In the presence of altered motility, this passive movement may result in limited visualisation of the bowel mucosa (and any lesion of interest) or lead to excessively slow or fast transit, reducing the device's diagnostic accuracy. Opportunity for therapeutic intervention may also be limited due to the difficulties with targeting a specific lesion or site in the gastrointestinal tract for treatment, sampling or drug delivery. Active manipulation of locomotion can be achieved through capsule design, which is mostly experimental, and includes capsule legs, , paddles and inchworm‐like manoeuvrability or can be externally controlled such as through the use of magnetic fields and/or external tethering such as string. , Active locomotion capabilities allow more intentional and targeted capsule movement to be achieved. Inhibition of locomotion may enable the device and its sensor to spend a prolonged period of time at a specific site in the gut, such as the Bravo™ pH capsule, which is endoscopically clipped to the distal oesophageal mucosa. Alternatively, the physical properties of the device may be designed in such a way that the effects of peristalsis are reduced, allowing increased gastric or intestinal residency time. For example, a device of low density was demonstrated to increase gastric residence time in a gastric physiology study in pigs, although such an approach might be challenging to safely apply in humans. This concept has been discussed in greater detail previously. 

THE LANDSCAPE OF INGESTIBLE SENSORS IN GASTROENTEROLOGY A wide spectrum of sensing tools have been applied to the human gastrointestinal tract measuring various aspects of gastrointestinal function and/or structure. To date, few have reached routine clinical practice, but several have promising development programs. Examples are outlined below. 5.1 Imaging the gastrointestinal tract The majority of imaging tools currently used in clinical practice have the potential to be adapted, miniaturised and incorporated into ingestible device technology. Examples are included in the following. Direct imaging : Direct imaging using capsule endoscopy represents a significant portion of the market for ingestible sensors. Video capsule endoscopy was first described in 2000 with the PillCam® (originally known as the M2A capsule, mouth to anus) first receiving FDA approval in 2001. , The images obtained from the most recent iterations of ingestible capsules with optical cameras are now of comparable resolution to fibre‐optic endoscopy. Details of how many of the technical challenges and obstacles have been overcome have been reviewed elsewhere. There are several video capsule endoscopy systems commercially available across the globe, including, the PillCam (Medtronic, Minneapolis, USA), which has various iterations specifically designed for endoluminal assessment of the oesophagus (e.g. PillCam ESO/Upper GI), small intestine (e.g. PillCam SB3) and large intestine (e.g. COLON2) , ; the EndoCapsule (Olympus, Tokyo, Japan) ; MiroCam (IntroMedic, Seoul, Korea) ; CapsoCam (Plus) (CapsoVision, Saratoga, USA) , and the OMOM capsule (Jianshan Science and Technology (Group) Co., Ltd., Chongqing, China). Wireless capsule systems continue to be refined. The commercially available capsules vary slightly in design, both in physical capsule characteristics and by function, including the lens field of view, how the images are captured, the frame rate of image acquisition, battery life, data viewing system and the need (or not) for post‐excretion capsule retrieval. , Capsule endoscopy technology is now considered the gold standard in the work‐up of obscure gastrointestinal bleeding and accounts for approximately two thirds of the capsule studies performed. The European Society of Gastrointestinal Endoscopy also reference the use of capsule endoscopy in various other scenarios, such as suspected small bowel Crohn's disease (in the absence of obstructive symptoms or obvious stricturing disease and negative ileocolonoscopy) and in certain clinical settings for surveillance of polyposis syndromes. , In established Crohn's disease, prior administration of a patency capsule may be appropriate to assess the risk of capsule retention. Other potential indications include NSAID enteropathy, after a recommended minimum 4‐week cessation, graft‐versus‐host disease and coeliac disease in certain clinical scenarios. , , Since gastric exit and caecal entry are readily identified by distinct imaging features, regional gastrointestinal transit times can also be calculated using the time of transit through these landmarks. Video capsule endoscopy has also been used to assess motility patterns in the small bowel and stomach. The failure rates of these devices relate largely to the passive nature of their transit, and are inherently at risk of missing lesions, depending on the direction and field of view of the lens, the lesion location and size, rate of intestinal transit and the bowel preparation. , Failure rates will also be influenced by the primary indication for the capsule endoscopy and the timing of administration of the capsule, for example, the diagnostic yield for capsule endoscopy in obscure gastrointestinal bleeding is higher if performed early (e.g. within 48–72 h of the bleeding event). , More advanced capsule endoscopy systems, including the OMOM capsule system, have duplex data transmission, which means that real‐time monitoring is possible with the ability to adjust the activity of the device, such as the image capture frequency and other image format characteristics (e.g. flash intensity and white balance) using a workstation, thereby enhancing small bowel examination. A number of magnetically‐controlled endoscopy systems have been developed since the original concept was proposed in 2006. , , , , , The magnetic control may be hand‐held, MRI‐based or robotic. , The use of a detachable string in conjunction with the magnetically controlled capsule endoscopy system (e.g. Ankon Technologies Co. Ltd, Shanghai, China) has been studied, to increase the assessment of the upper gastrointestinal tract, particularly the oesophagus. , , The application of magnetically‐controlled capsules in gastric disease assessment has been reviewed in detail previously. Robotically‐assisted magnetic endoscopy systems have also been described, including those, in‐concept, which can be anally inserted and used in the assessment of colonic pathology. , Optical sensors : Reflection, absorption, transmission and scattering of light can be measured by optical sensors. An example of such sensors is the telemetric bleeding sensor (HemoPill, Ovesco Endoscopy Endoscopy AG, Tuebingen, Germany), where the ratio of red and violet light measured by an LED (light emitting diode) sensor can detect blood, in a non‐fasted patient, which has the potential to allow rapid assessment and triaging of patients presenting with possible upper gastrointestinal bleeding. , The obvious downside to this is that no intervention can be applied when bleeding is identified. Sonographic transducers : Ultrasound capsule endoscopy (USCE) performs transmural imaging and both qualitative and quantitative assessment of the gastrointestinal tract wall, in contrast to optical imaging (e.g. video capsule endoscopy) which is generally limited to assessment of the mucosal surface. Micro‐ultrasound waves are high in frequency (>20 MHz) and provide shallow but high‐resolution imaging, which has been shown to correlate with histological findings. , , The therapeutic and interventional capabilities of these transducers have been evaluated in proof‐of‐concept studies and include applications such as ultrasound‐mediated targeted drug delivery. Transient permeabilisation of the mucosal membrane may be achieved using this technology enabling molecular diffusion. , , The SonoPill capsule system was being developed with diagnostic and therapeutic capabilities in mind, but has now been discontinued. , Research and development continues in this field and includes robotically‐controlled ultrasound capsule technology. , X‐ray sensors : Radiological assessment of the large intestine has been achieved using X‐ray technology, with short‐lived radioisotope emitting low‐dose X‐ray beams from an ingested device, equivalent to one chest X‐ray. The patients ingest a small volume of radiopaque contrast agent in lieu of bowel preparation. The position of the device can then be tracked using a 3D accelerometer and 3D magnetometer. The data obtained enable a three‐dimensional reconstruction of the colon to be achieved with certain polyps and other lesions identifiable depending on their size and morphology. There may be a role for a diagnostic capsule such as this in screening patients not willing or able to proceed in the first instance to a colonoscopy. However, the device itself does not have therapeutic capability, such as polypectomy, so may not obviate the need for colonoscopy. 5.2 Sensors of position and orientation Radiofrequency identification (RFID) sensors : Devices containing elements capable of interacting with electromagnetic waves are able to be detected by radiofrequency and are the basis for the dissolvable patency capsules used to assess the risk of capsule retention. Spatiotemporal analysis : Spatiotemporal analysis of an ingestible device in the gastrointestinal tract is possible using magnetic tracking technology, in which position and angle coordinates are derived from electromagnetic fields. Position coordinates reflect the capsule's three‐dimensional spatial position, which allows transit time between two anatomical locations to be calculated. Angular coordinates, on the contrary, serve as a surrogate of intestinal contraction frequency, which is different in each region of the gastrointestinal tract. This area of development is very active with several prototypes described. The earliest system using this technology was the Magnet Tracking System (MTS‐1), comprising of a stationary detector for the patient to lie on, a small ingestible magnetic ‘pill’, a calibrated detection matrix with multiple magnetic field sensors (worn across the subject's abdomen) and software to analyse the output. , , By contrast, the more recent 3D transit electromagnetic system (Motilis Medica, SA, Lausanne, Switzerland) is an ambulatory system that uses a portable detector. The system has been used in the assessment of regional and whole gut transit and colorectum length, motility and colonic segmental transit time. , , , , An ambulatory system using electromagnetic coils, known as the iMAG system (ingestible microdevices for anatomical mapping of the gastrointestinal tract), is in the early stages of development. Such a system may have a potential role in the assessment of gastrointestinal transit and in combination with other devices to enable targeted delivery due to its localisation capability. Accelerometer : This detects motion by measuring the rate of change of movement over time. These sensors are commonly marketed for health and lifestyle movement tracking and have been incorporated in several ingestible electronic devices for localisation purposes (e.g. Atmo gas‐sensing capsule) and to help measure movement artefact (e.g. 3D transit electromagnetic system). , , , 5.3 Chemosensors pH assessment has been used to assess various aspects of the gastrointestinal system. , , From the distal oesophagus, in the measurement of gastroesophageal reflux, to caecal fermentation in the large intestine. The Bravo catheter‐free pH monitoring system, for example, measures acid exposure for an extended period (>36 h in 89% of patients) after being endoscopically clipped to the distal oesophagus (Bravo, Medtronic/Synectics, USA). The device is well‐tolerated overall, although non‐cardiac chest pain is experienced at increased frequency compared with controls. , The OMOM pH capsule (Chongqing Jinshan Science and Technology Group Co., Ltd, Beijing, China) similarly, measures oesophageal acid exposure by monitoring pH for extended periods up to 96 h in duration. A magnetically‐held pH and impedance monitoring capsule device was reported in concept some time ago but does not appear to have progressed. The principal sensor in the SmartPill® WMC monitoring system is a pH sensor. , , The presence of predictable pH changes along the tract allows the capsule to be localised during its transit through the gastrointestinal tract. These changes include an abrupt and sustained rise in pH that occurs on transition from the acidic environment of the stomach to the bicarbonate‐rich environment of the duodenum (pH 5.9–6.8) and then the abrupt fall in pH from the alkaline ileum (pH ~7.3–7.7) to the acidic caecum/proximal ascending colon (pH 5.8–6.7), occurring secondary to the production of weak acids, such as short‐chain fatty acids, from carbohydrate fermentation. , , , The WMC was approved by the FDA in 2006 for evaluating gastric emptying and colonic transit times in suspected gastroparesis and slow‐transit constipation, respectively and it has also been used to evaluate colonic fermentation in the colon, but with less validation. , , In June 2023 it was announced that WMC production will be terminated. An alternative ingestible pH‐sensing capsule, which is low in cost, has recently been reported and further studies are awaited. Reactive oxygen species are able to be measured using electrochemical sensors and have been described in proof‐of‐concept recently, combined with a pH sensor to help localise the capsule within the gastrointestinal tract. It has been proposed as an alternative biomarker to assess inflammation, such as in inflammatory bowel disease. 5.4 Gas sensors Gases are valuable biomarkers in the gut. The Atmo gas‐sensing capsule (Atmo Biosciences, Box Hill, Australia) is a novel ingestible device that houses analyte sensors capable of measuring hydrogen and carbon dioxide concentrations using thermal conductivity detectors, a multi‐gas detector via a volatile organic compound sensor and also measures temperature, capsule orientation and antennae efficiency. , Measurements are transmitted from the capsule at a frequency of 434 MHz to a patient‐worn data receiver and subsequently uploaded to a remote server via a mobile device application for analysis and review via a web portal. It has been demonstrated to assess major gastrointestinal landmarks accurately in healthy subjects and a pilot study of gastroparesis and slow transit constipation and is being validated in larger trials for transit assessment presently. , Analysis of gas profiles may also enable additional physiological processes to be described, including colonic fermentation and small intestinal bacterial overgrowth (SIBO). A prototype capsule system detecting hydrogen sulphide has also recently been described. 5.5 Microbiological‐based sensors Genetically modified probiotic sensor bacteria can be used to help detect specific analytes in the gastrointestinal tract lumen. The Ingestible Micro‐Bio‐Electronic Device (IMBED) comprises a semi‐permeable membrane that separates the luminal space from an inner chamber holding genetically modified probiotic E. coli Nissle 1917. It has been described in proof‐of‐concept to detect heme, and has been expanded to detect other biomarkers, such as tetrathionate, which measures inflammation and acyl‐homoserine lactone, which is a signature of particular bacteria, which can be commensal or pathogenic. Further advances have led to a biosensing panel for nitric oxide, hydrogen peroxide, thiosulfate and tetrathionate, housed in a device that has been miniaturised to the extent that it can be safely orally ingested. , A novel sensing system that measures bacterial counts based on fluorometric signals, has been recently described in preliminary reports for small intestinal bacterial overgrowth. , Formal reporting of this study is awaited. 5.6 Pressure sensors The SmartPill WMC houses two other sensors in addition to the pH sensor, including a single pressure sensor (measurement range 0 to 350 mmHg) (and the temperature sensor discussed below). This sensor has been used to assess gastrointestinal tract contractile frequency in healthy and gastroparetic subjects, although the clinical interpretation of these measures requires further consideration. One of the major difficulties interpreting pressure sensor data relates to the artefact generated from abdominal/body movement and transthoracic respiratory‐related movement. The inability to sub‐localise the device's location (e.g. antrum vs body vs fundus of stomach) is relevant, for example, in the evaluation of suspected gastric dysmotility, where the ability to differentially evaluate antral motility from fundus motility may be beneficial. Pressure sensor use has also been evaluated in a pilot study of acute abdominal compartment syndrome in pigs using an ingestible microelectromechanical system (PressureDOT, 10 mm × 13 mm). Further work is required to assess its clinical applicability in humans. 5.7 Temperature sensors Temperature sensors are common components of ingestible devices. Devices with a specific role in assessing core body temperature were first described in 1968 and remain commonly used in athletes or occupations involving thermally harsh environments. Examples include CorTemp Pill® (HQ Inc, USA) and its current version BodyCap—e‐Celsius performance pill (BodyCap, France), the VitalSense® capsule (Philips, USA) and the battery‐free, magnetically‐powered, myTemp (Nimegen, Netherlands). Other systems, such as the SmartPill WMC and Atmo Gas‐sensing capsule, use temperature sensors as adjunctive sensors, to confirm device ingestion (i.e. an increase in temperature relative to ambient temperature) and excretion (i.e. confirmed by a drop in temperature from body temperature to environmental). 

Imaging the gastrointestinal tract The majority of imaging tools currently used in clinical practice have the potential to be adapted, miniaturised and incorporated into ingestible device technology. Examples are included in the following. Direct imaging : Direct imaging using capsule endoscopy represents a significant portion of the market for ingestible sensors. Video capsule endoscopy was first described in 2000 with the PillCam® (originally known as the M2A capsule, mouth to anus) first receiving FDA approval in 2001. , The images obtained from the most recent iterations of ingestible capsules with optical cameras are now of comparable resolution to fibre‐optic endoscopy. Details of how many of the technical challenges and obstacles have been overcome have been reviewed elsewhere. There are several video capsule endoscopy systems commercially available across the globe, including, the PillCam (Medtronic, Minneapolis, USA), which has various iterations specifically designed for endoluminal assessment of the oesophagus (e.g. PillCam ESO/Upper GI), small intestine (e.g. PillCam SB3) and large intestine (e.g. COLON2) , ; the EndoCapsule (Olympus, Tokyo, Japan) ; MiroCam (IntroMedic, Seoul, Korea) ; CapsoCam (Plus) (CapsoVision, Saratoga, USA) , and the OMOM capsule (Jianshan Science and Technology (Group) Co., Ltd., Chongqing, China). Wireless capsule systems continue to be refined. The commercially available capsules vary slightly in design, both in physical capsule characteristics and by function, including the lens field of view, how the images are captured, the frame rate of image acquisition, battery life, data viewing system and the need (or not) for post‐excretion capsule retrieval. , Capsule endoscopy technology is now considered the gold standard in the work‐up of obscure gastrointestinal bleeding and accounts for approximately two thirds of the capsule studies performed. The European Society of Gastrointestinal Endoscopy also reference the use of capsule endoscopy in various other scenarios, such as suspected small bowel Crohn's disease (in the absence of obstructive symptoms or obvious stricturing disease and negative ileocolonoscopy) and in certain clinical settings for surveillance of polyposis syndromes. , In established Crohn's disease, prior administration of a patency capsule may be appropriate to assess the risk of capsule retention. Other potential indications include NSAID enteropathy, after a recommended minimum 4‐week cessation, graft‐versus‐host disease and coeliac disease in certain clinical scenarios. , , Since gastric exit and caecal entry are readily identified by distinct imaging features, regional gastrointestinal transit times can also be calculated using the time of transit through these landmarks. Video capsule endoscopy has also been used to assess motility patterns in the small bowel and stomach. The failure rates of these devices relate largely to the passive nature of their transit, and are inherently at risk of missing lesions, depending on the direction and field of view of the lens, the lesion location and size, rate of intestinal transit and the bowel preparation. , Failure rates will also be influenced by the primary indication for the capsule endoscopy and the timing of administration of the capsule, for example, the diagnostic yield for capsule endoscopy in obscure gastrointestinal bleeding is higher if performed early (e.g. within 48–72 h of the bleeding event). , More advanced capsule endoscopy systems, including the OMOM capsule system, have duplex data transmission, which means that real‐time monitoring is possible with the ability to adjust the activity of the device, such as the image capture frequency and other image format characteristics (e.g. flash intensity and white balance) using a workstation, thereby enhancing small bowel examination. A number of magnetically‐controlled endoscopy systems have been developed since the original concept was proposed in 2006. , , , , , The magnetic control may be hand‐held, MRI‐based or robotic. , The use of a detachable string in conjunction with the magnetically controlled capsule endoscopy system (e.g. Ankon Technologies Co. Ltd, Shanghai, China) has been studied, to increase the assessment of the upper gastrointestinal tract, particularly the oesophagus. , , The application of magnetically‐controlled capsules in gastric disease assessment has been reviewed in detail previously. Robotically‐assisted magnetic endoscopy systems have also been described, including those, in‐concept, which can be anally inserted and used in the assessment of colonic pathology. , Optical sensors : Reflection, absorption, transmission and scattering of light can be measured by optical sensors. An example of such sensors is the telemetric bleeding sensor (HemoPill, Ovesco Endoscopy Endoscopy AG, Tuebingen, Germany), where the ratio of red and violet light measured by an LED (light emitting diode) sensor can detect blood, in a non‐fasted patient, which has the potential to allow rapid assessment and triaging of patients presenting with possible upper gastrointestinal bleeding. , The obvious downside to this is that no intervention can be applied when bleeding is identified. Sonographic transducers : Ultrasound capsule endoscopy (USCE) performs transmural imaging and both qualitative and quantitative assessment of the gastrointestinal tract wall, in contrast to optical imaging (e.g. video capsule endoscopy) which is generally limited to assessment of the mucosal surface. Micro‐ultrasound waves are high in frequency (>20 MHz) and provide shallow but high‐resolution imaging, which has been shown to correlate with histological findings. , , The therapeutic and interventional capabilities of these transducers have been evaluated in proof‐of‐concept studies and include applications such as ultrasound‐mediated targeted drug delivery. Transient permeabilisation of the mucosal membrane may be achieved using this technology enabling molecular diffusion. , , The SonoPill capsule system was being developed with diagnostic and therapeutic capabilities in mind, but has now been discontinued. , Research and development continues in this field and includes robotically‐controlled ultrasound capsule technology. , X‐ray sensors : Radiological assessment of the large intestine has been achieved using X‐ray technology, with short‐lived radioisotope emitting low‐dose X‐ray beams from an ingested device, equivalent to one chest X‐ray. The patients ingest a small volume of radiopaque contrast agent in lieu of bowel preparation. The position of the device can then be tracked using a 3D accelerometer and 3D magnetometer. The data obtained enable a three‐dimensional reconstruction of the colon to be achieved with certain polyps and other lesions identifiable depending on their size and morphology. There may be a role for a diagnostic capsule such as this in screening patients not willing or able to proceed in the first instance to a colonoscopy. However, the device itself does not have therapeutic capability, such as polypectomy, so may not obviate the need for colonoscopy. 

Sensors of position and orientation Radiofrequency identification (RFID) sensors : Devices containing elements capable of interacting with electromagnetic waves are able to be detected by radiofrequency and are the basis for the dissolvable patency capsules used to assess the risk of capsule retention. Spatiotemporal analysis : Spatiotemporal analysis of an ingestible device in the gastrointestinal tract is possible using magnetic tracking technology, in which position and angle coordinates are derived from electromagnetic fields. Position coordinates reflect the capsule's three‐dimensional spatial position, which allows transit time between two anatomical locations to be calculated. Angular coordinates, on the contrary, serve as a surrogate of intestinal contraction frequency, which is different in each region of the gastrointestinal tract. This area of development is very active with several prototypes described. The earliest system using this technology was the Magnet Tracking System (MTS‐1), comprising of a stationary detector for the patient to lie on, a small ingestible magnetic ‘pill’, a calibrated detection matrix with multiple magnetic field sensors (worn across the subject's abdomen) and software to analyse the output. , , By contrast, the more recent 3D transit electromagnetic system (Motilis Medica, SA, Lausanne, Switzerland) is an ambulatory system that uses a portable detector. The system has been used in the assessment of regional and whole gut transit and colorectum length, motility and colonic segmental transit time. , , , , An ambulatory system using electromagnetic coils, known as the iMAG system (ingestible microdevices for anatomical mapping of the gastrointestinal tract), is in the early stages of development. Such a system may have a potential role in the assessment of gastrointestinal transit and in combination with other devices to enable targeted delivery due to its localisation capability. Accelerometer : This detects motion by measuring the rate of change of movement over time. These sensors are commonly marketed for health and lifestyle movement tracking and have been incorporated in several ingestible electronic devices for localisation purposes (e.g. Atmo gas‐sensing capsule) and to help measure movement artefact (e.g. 3D transit electromagnetic system). , , , 

Chemosensors pH assessment has been used to assess various aspects of the gastrointestinal system. , , From the distal oesophagus, in the measurement of gastroesophageal reflux, to caecal fermentation in the large intestine. The Bravo catheter‐free pH monitoring system, for example, measures acid exposure for an extended period (>36 h in 89% of patients) after being endoscopically clipped to the distal oesophagus (Bravo, Medtronic/Synectics, USA). The device is well‐tolerated overall, although non‐cardiac chest pain is experienced at increased frequency compared with controls. , The OMOM pH capsule (Chongqing Jinshan Science and Technology Group Co., Ltd, Beijing, China) similarly, measures oesophageal acid exposure by monitoring pH for extended periods up to 96 h in duration. A magnetically‐held pH and impedance monitoring capsule device was reported in concept some time ago but does not appear to have progressed. The principal sensor in the SmartPill® WMC monitoring system is a pH sensor. , , The presence of predictable pH changes along the tract allows the capsule to be localised during its transit through the gastrointestinal tract. These changes include an abrupt and sustained rise in pH that occurs on transition from the acidic environment of the stomach to the bicarbonate‐rich environment of the duodenum (pH 5.9–6.8) and then the abrupt fall in pH from the alkaline ileum (pH ~7.3–7.7) to the acidic caecum/proximal ascending colon (pH 5.8–6.7), occurring secondary to the production of weak acids, such as short‐chain fatty acids, from carbohydrate fermentation. , , , The WMC was approved by the FDA in 2006 for evaluating gastric emptying and colonic transit times in suspected gastroparesis and slow‐transit constipation, respectively and it has also been used to evaluate colonic fermentation in the colon, but with less validation. , , In June 2023 it was announced that WMC production will be terminated. An alternative ingestible pH‐sensing capsule, which is low in cost, has recently been reported and further studies are awaited. Reactive oxygen species are able to be measured using electrochemical sensors and have been described in proof‐of‐concept recently, combined with a pH sensor to help localise the capsule within the gastrointestinal tract. It has been proposed as an alternative biomarker to assess inflammation, such as in inflammatory bowel disease. 

Gas sensors Gases are valuable biomarkers in the gut. The Atmo gas‐sensing capsule (Atmo Biosciences, Box Hill, Australia) is a novel ingestible device that houses analyte sensors capable of measuring hydrogen and carbon dioxide concentrations using thermal conductivity detectors, a multi‐gas detector via a volatile organic compound sensor and also measures temperature, capsule orientation and antennae efficiency. , Measurements are transmitted from the capsule at a frequency of 434 MHz to a patient‐worn data receiver and subsequently uploaded to a remote server via a mobile device application for analysis and review via a web portal. It has been demonstrated to assess major gastrointestinal landmarks accurately in healthy subjects and a pilot study of gastroparesis and slow transit constipation and is being validated in larger trials for transit assessment presently. , Analysis of gas profiles may also enable additional physiological processes to be described, including colonic fermentation and small intestinal bacterial overgrowth (SIBO). A prototype capsule system detecting hydrogen sulphide has also recently been described. 

Microbiological‐based sensors Genetically modified probiotic sensor bacteria can be used to help detect specific analytes in the gastrointestinal tract lumen. The Ingestible Micro‐Bio‐Electronic Device (IMBED) comprises a semi‐permeable membrane that separates the luminal space from an inner chamber holding genetically modified probiotic E. coli Nissle 1917. It has been described in proof‐of‐concept to detect heme, and has been expanded to detect other biomarkers, such as tetrathionate, which measures inflammation and acyl‐homoserine lactone, which is a signature of particular bacteria, which can be commensal or pathogenic. Further advances have led to a biosensing panel for nitric oxide, hydrogen peroxide, thiosulfate and tetrathionate, housed in a device that has been miniaturised to the extent that it can be safely orally ingested. , A novel sensing system that measures bacterial counts based on fluorometric signals, has been recently described in preliminary reports for small intestinal bacterial overgrowth. , Formal reporting of this study is awaited. 

Pressure sensors The SmartPill WMC houses two other sensors in addition to the pH sensor, including a single pressure sensor (measurement range 0 to 350 mmHg) (and the temperature sensor discussed below). This sensor has been used to assess gastrointestinal tract contractile frequency in healthy and gastroparetic subjects, although the clinical interpretation of these measures requires further consideration. One of the major difficulties interpreting pressure sensor data relates to the artefact generated from abdominal/body movement and transthoracic respiratory‐related movement. The inability to sub‐localise the device's location (e.g. antrum vs body vs fundus of stomach) is relevant, for example, in the evaluation of suspected gastric dysmotility, where the ability to differentially evaluate antral motility from fundus motility may be beneficial. Pressure sensor use has also been evaluated in a pilot study of acute abdominal compartment syndrome in pigs using an ingestible microelectromechanical system (PressureDOT, 10 mm × 13 mm). Further work is required to assess its clinical applicability in humans. 

Temperature sensors Temperature sensors are common components of ingestible devices. Devices with a specific role in assessing core body temperature were first described in 1968 and remain commonly used in athletes or occupations involving thermally harsh environments. Examples include CorTemp Pill® (HQ Inc, USA) and its current version BodyCap—e‐Celsius performance pill (BodyCap, France), the VitalSense® capsule (Philips, USA) and the battery‐free, magnetically‐powered, myTemp (Nimegen, Netherlands). Other systems, such as the SmartPill WMC and Atmo Gas‐sensing capsule, use temperature sensors as adjunctive sensors, to confirm device ingestion (i.e. an increase in temperature relative to ambient temperature) and excretion (i.e. confirmed by a drop in temperature from body temperature to environmental). 

INTERVENTIONAL FUNCTIONS OF INGESTIBLE DEVICES Just as the clinical power of endoscopic examination of the gastrointestinal tract has been greatly enhanced by the ability to intervene with diagnostic and therapeutic actions, developing a device that has the capability of performing a ‘function’ during its transit through the gastrointestinal tract represents the next challenge for capsule technology. Various mechanisms may enable these functions to be performed, such as electrical, electrochemical, acoustic and thermal processes, leading, for example, to the opening of cavities for the targeted release of stored drugs or obtaining luminal samples. Multiple applications have been evaluated to date and examples are outlined below. 6.1 Assessment of drug adherence Drug adherence is a significant issue in the management of chronic diseases, with rates as low as 30%–35% reported. , The first digital ingestion tracking system to monitor drug adherence was approved by the FDA in 2017 and consisted of a drug (aripiprazole) with an embedded ingestible sensor (Abilify MyCite, Otsuka Pharmaceutical Co. Ltd). This digital pill is activated in the stomach and interacts with a wearable ‘patch’, which communicates with a mobile application via Bluetooth® to confirm drug ingestion. Digital medication compliance has also been studied in other clinical settings in proof‐of‐concept and feasibility studies, including post‐renal transplant and treatment of tuberculosis. 6.2 Drug delivery In concept, ingestible devices offer a promising tool for targeted drug delivery to specific sites of the gastrointestinal tract. These may also provide a conduit for drugs that are considered otherwise unsuitable for oral delivery, such as peptides, which may be susceptible to enzymatic degradation, or likely to exhibit impaired absorption due to altered intestinal transit. Various mechanisms for drug delivery have been reported, with drug release under active or passive control. Passive release, for example, may be triggered by an external radiofrequency signal‐generated heat‐induced release of a spring, such as in the IntelliSite capsule (Scintipharma Inc., Lexington, KY, USA), while active release may occur, for example, via a motor‐controlled piston that can be activated manually using wireless data exchange or automatically, as seen in the IntelliCap capsule (Medimetrics Personalised Drug Delivery). The IntelliCap capsule contains a drug reservoir as well as pH and temperature sensors to help localise the capsule in the gastrointestinal tract in real‐time to allow targeted drug delivery. , , Such capsules can also be used for measuring gastrointestinal transit times and drug pharmacokinetics, and play a role in the assessment of regional drug absorption in clinical studies. , , Magnetic drug delivery devices, including robotic devices, have been designed but require ongoing refinement before they will be ready for clinical trials. , Various other models of drug delivery have been explored, including capsules with adhesion mechanisms to allow a sustained drug release, microneedle drug delivery technology, use of micromotors and the earlier mentioned ultrasound technology designed to increase mucosal permeability to drugs. , , , , , , , Electronic drug delivery devices have been reviewed in detail recently. 6.3 Direct gastrointestinal tract sampling Direct sampling of the gastrointestinal tract remains an important target in electronic device research and development, and would greatly enhance our understanding of gastrointestinal physiology and the microbiome in an unperturbed state. Most devices remain as aspirational projects and few, if any, are at the stage of commercialisation. The major challenges with these ingestible devices relate to obtaining a sufficient sample, that is leak‐proof, protected from contamination or alteration from gastrointestinal secretions and microbial metabolic activity and able to be accurately localised within the gastrointestinal tract to ensure that the site of sample is known, while remaining small enough to be safely ingested and delicate enough so as not to cause intestinal damage during the sampling process. The devices in the pipeline employ various techniques, such as spring‐loading, suction and osmosis, for example, to obtain gastrointestinal tract samples in one or more collecting channels and many remain electronic‐free. , , Tethered, non‐electronic capsules, such as the Krosby‐Kugler capsule, were used as early as the 1950s to collect small bowel samples. , A modified Intellicap system has recently been described and includes a collecting chamber for microbiome sampling and illustrates the expansive flexibility these technologies offer. , Various sampling devices have been described in prototype form, including a device able to collect small sample volumes in ex vivo and pig models, and a wireless device with magnetic actuation system, which is yet to be reported in vivo. , , , , Active control over timing and localisation of sampling remains under development, and advances in robotic technology will undoubtedly overcome many of these current limitations in the future. , At this stage, despite multiple reports describing novel designs with claims of proof‐of‐concept, none have provided key peer‐reviewed data that move the concepts into the realm of clinical reality. A logistical issue that is not likely to be overcome in the near future is the need to retrieve the excreted device in order to analyse the sampled material. 6.4 Vibration as the therapeutic intervention Vibrating ingestible devices have been described recently for the management of constipation. ‘Vibrant’, a vibrating device marketed in the United States, received FDA approval for use in chronic idiopathic constipation in 2022 (Vibrant Ltd, Hakochav Yokneam, Israel). The battery‐operated device is encapsulated in a latex‐free plastic shell and contains a microchip and vibrating motor. , , It has been evaluated in a phase III randomised placebo‐controlled trial involving daily device ingestion (between 9 and 10 pm each day), 5 days a week for 8 weeks, with a pre‐programmed vibration schedule. Improvements in complete spontaneous bowel movements and stool characteristics were reported. Similar studies in China have been conducted using a vibrating electronic device (27 mm × 12 mm) which is activated via a smartphone (Vibravot, Ankon Medical Technology Co., Ltd). The 6‐h vibrating sequence is also pre‐programmed, designed to begin 8 h post‐ingestion but also has the ability to be externally controlled by a phone or configuration device. 6.5 Other therapeutic interventions The myriad of therapeutic interventional techniques capable of being performed by electronic devices seems only restricted by one's imagination. For example, robotic electroceutical capsules that, by delivering controlled electrical stimulation to the enteric nervous system, might influence local motility, such as gastric emptying, or the gut‐brain axis, such as by modulating hunger‐related hormones and intra‐gastric balloon capsules for obesity management are under development or have been proposed. Robotic control of gastrointestinal haemorrhage has been proposed based on the detection of bleeding detected by blood‐coloured pixels with subsequent inflation of a balloon from an endothermic reaction to apply pressure to the site of haemorrhage, or by magnetically steering a device with a surgical clip in situ, which is able to be deployed at the site of bleeding. Origami robots that unfold from a swallowed device and are subsequently controlled by external magnetic fields can be directed to perform a therapeutic function, like removing a swallowed button battery or patching a wound, which have also been proposed. 

Assessment of drug adherence Drug adherence is a significant issue in the management of chronic diseases, with rates as low as 30%–35% reported. , The first digital ingestion tracking system to monitor drug adherence was approved by the FDA in 2017 and consisted of a drug (aripiprazole) with an embedded ingestible sensor (Abilify MyCite, Otsuka Pharmaceutical Co. Ltd). This digital pill is activated in the stomach and interacts with a wearable ‘patch’, which communicates with a mobile application via Bluetooth® to confirm drug ingestion. Digital medication compliance has also been studied in other clinical settings in proof‐of‐concept and feasibility studies, including post‐renal transplant and treatment of tuberculosis. 

Drug delivery In concept, ingestible devices offer a promising tool for targeted drug delivery to specific sites of the gastrointestinal tract. These may also provide a conduit for drugs that are considered otherwise unsuitable for oral delivery, such as peptides, which may be susceptible to enzymatic degradation, or likely to exhibit impaired absorption due to altered intestinal transit. Various mechanisms for drug delivery have been reported, with drug release under active or passive control. Passive release, for example, may be triggered by an external radiofrequency signal‐generated heat‐induced release of a spring, such as in the IntelliSite capsule (Scintipharma Inc., Lexington, KY, USA), while active release may occur, for example, via a motor‐controlled piston that can be activated manually using wireless data exchange or automatically, as seen in the IntelliCap capsule (Medimetrics Personalised Drug Delivery). The IntelliCap capsule contains a drug reservoir as well as pH and temperature sensors to help localise the capsule in the gastrointestinal tract in real‐time to allow targeted drug delivery. , , Such capsules can also be used for measuring gastrointestinal transit times and drug pharmacokinetics, and play a role in the assessment of regional drug absorption in clinical studies. , , Magnetic drug delivery devices, including robotic devices, have been designed but require ongoing refinement before they will be ready for clinical trials. , Various other models of drug delivery have been explored, including capsules with adhesion mechanisms to allow a sustained drug release, microneedle drug delivery technology, use of micromotors and the earlier mentioned ultrasound technology designed to increase mucosal permeability to drugs. , , , , , , , Electronic drug delivery devices have been reviewed in detail recently. 

Direct gastrointestinal tract sampling Direct sampling of the gastrointestinal tract remains an important target in electronic device research and development, and would greatly enhance our understanding of gastrointestinal physiology and the microbiome in an unperturbed state. Most devices remain as aspirational projects and few, if any, are at the stage of commercialisation. The major challenges with these ingestible devices relate to obtaining a sufficient sample, that is leak‐proof, protected from contamination or alteration from gastrointestinal secretions and microbial metabolic activity and able to be accurately localised within the gastrointestinal tract to ensure that the site of sample is known, while remaining small enough to be safely ingested and delicate enough so as not to cause intestinal damage during the sampling process. The devices in the pipeline employ various techniques, such as spring‐loading, suction and osmosis, for example, to obtain gastrointestinal tract samples in one or more collecting channels and many remain electronic‐free. , , Tethered, non‐electronic capsules, such as the Krosby‐Kugler capsule, were used as early as the 1950s to collect small bowel samples. , A modified Intellicap system has recently been described and includes a collecting chamber for microbiome sampling and illustrates the expansive flexibility these technologies offer. , Various sampling devices have been described in prototype form, including a device able to collect small sample volumes in ex vivo and pig models, and a wireless device with magnetic actuation system, which is yet to be reported in vivo. , , , , Active control over timing and localisation of sampling remains under development, and advances in robotic technology will undoubtedly overcome many of these current limitations in the future. , At this stage, despite multiple reports describing novel designs with claims of proof‐of‐concept, none have provided key peer‐reviewed data that move the concepts into the realm of clinical reality. A logistical issue that is not likely to be overcome in the near future is the need to retrieve the excreted device in order to analyse the sampled material. 

Vibration as the therapeutic intervention Vibrating ingestible devices have been described recently for the management of constipation. ‘Vibrant’, a vibrating device marketed in the United States, received FDA approval for use in chronic idiopathic constipation in 2022 (Vibrant Ltd, Hakochav Yokneam, Israel). The battery‐operated device is encapsulated in a latex‐free plastic shell and contains a microchip and vibrating motor. , , It has been evaluated in a phase III randomised placebo‐controlled trial involving daily device ingestion (between 9 and 10 pm each day), 5 days a week for 8 weeks, with a pre‐programmed vibration schedule. Improvements in complete spontaneous bowel movements and stool characteristics were reported. Similar studies in China have been conducted using a vibrating electronic device (27 mm × 12 mm) which is activated via a smartphone (Vibravot, Ankon Medical Technology Co., Ltd). The 6‐h vibrating sequence is also pre‐programmed, designed to begin 8 h post‐ingestion but also has the ability to be externally controlled by a phone or configuration device. 

Other therapeutic interventions The myriad of therapeutic interventional techniques capable of being performed by electronic devices seems only restricted by one's imagination. For example, robotic electroceutical capsules that, by delivering controlled electrical stimulation to the enteric nervous system, might influence local motility, such as gastric emptying, or the gut‐brain axis, such as by modulating hunger‐related hormones and intra‐gastric balloon capsules for obesity management are under development or have been proposed. Robotic control of gastrointestinal haemorrhage has been proposed based on the detection of bleeding detected by blood‐coloured pixels with subsequent inflation of a balloon from an endothermic reaction to apply pressure to the site of haemorrhage, or by magnetically steering a device with a surgical clip in situ, which is able to be deployed at the site of bleeding. Origami robots that unfold from a swallowed device and are subsequently controlled by external magnetic fields can be directed to perform a therapeutic function, like removing a swallowed button battery or patching a wound, which have also been proposed. 

INGESTIBLE ELECTRONIC DEVICES IN CLINICAL PRACTICE The roles, potential or current, of ingestible electronic devices are summarised according to gastrointestinal regions in Figure . There are several important considerations required during the development of a device intended for clinical use, which are outlined in Table . Beyond the obvious technical issues of developing the device itself and ensuring it is safe, reliable and affordable, the incorporation of these technologies into clinical practice requires multidisciplinary collaboration. This is to ensure the device is measuring something that is of clinical relevance, be it for understanding an individual's physiology or a specific pathophysiological process and, ultimately, is what a clinician needs and wants when treating their patients. Validating the information captured by this technology to confirm it is real and accurate is challenging when there may be no precedent information available for comparison. A second challenge relates to incorporating this new biological or physiological information into established clinical algorithms. Thirdly, the demonstration of cost‐effectiveness so that this innovative technology and information can be translated into clinical funding models is essential in the current tight economic climate. In the earlier stages of research and development of these devices, funding is even more challenging, due to the high costs of running development programs and the extensive investigations required to prove efficacy and commercial viability and, ultimately, administrative approval be it FDA or TGA. However, over the longer term, ingestible electronic devices have the potential to be a cost‐effective tool due to the lack of stationary equipment required to gather the data in a patient who often can remain ambulatory and in an outpatient setting. In fact, these technologies have the potential to provide far‐reaching access to healthcare tests that would otherwise be inaccessible without dedicated travel to a hospital or medical centre. The story of capsule endoscopy has demonstrated that new technologies can be successfully incorporated into clinical practice and funding models. Its clinical acceptability and application were facilitated by the fact that endoscopic imaging of gastrointestinal mucosa was already standard practice. Hence, the introduction of a low‐risk method of visualising the entire small intestine was eagerly endorsed by the gastroenterological community. By contrast, the introduction of a validated, low‐risk and convenient method of measuring regional transit times (i.e. the SmartPill) was limited. This may have been related to the uncertainty of the impact of the unique data obtained on clinical decision‐making despite the demonstration of its value and inability in many environments to gain funding for its use due to uncertain cost–benefit (i.e. it was perceived as unaffordable). As ingestible device technology expands, more examples of this will arise and will be associated with these clinical challenges. The recent novel demonstration that the locoregional colonic distribution of carbohydrate fermentation, and thus short‐chain fatty acid delivery, can be evaluated using hydrogen concentrations is another example. Colonic fermentation and where it is occurring in the colon are not mainstream concerns for clinicians because such knowledge has had no prior clinical correlate or measurement until now and so it is likely that the clinical impact and awareness of this new information will take some time to be established. 7.1 Safety practice points for consideration with ingestible devices In general, the safety profiles of the ingestible devices currently commercially available are acceptable with infrequent reporting of serious complications. Ultimately, the nature and magnitude of the risks are dependent on the type of device being used and its indication. The clinician should take into consideration these risks, as outlined in Table . Clearly, some of these clinical scenarios have little to no data upon which the risk can be quantified, but the balance of risk and benefit still has to be evaluated in line with good clinical practice. One particular adverse event is capsule retention, defined as retention of the device within the gastrointestinal tract for 2 weeks or more. Small devices (e.g. less than 11 mm × 26 mm) of low density have minimal risk of retention in a healthy individual and can pass through the narrowest region of the gastrointestinal tract, the pylorus. Reported retention rates vary according to the specific device and its indication for use, ranging from 0.3% for WMC transit assessment and about 2% up to 8.2% in capsule endoscopy for suspected small bowel bleeding and established inflammatory bowel disease, respectively. , Patency capsules, such as the Agile Patency Capsule, as discussed earlier, may be used to assess the risk of retention (measuring 26 mm × 11 mm). Whether the patency capsule used needs to be an exact replica of the intended test device in terms of size and density, or whether a similar device can be used, is uncertain. Capsule retention management may be simply observational in nature or require endoscopic or surgical retrieval, which will be determined by the location of the retained capsule and whether the patient is symptomatic. Problems associated with swallowing devices have been reported uncommonly. For example, post‐marketing studies report a rate of 0.6% for swallowing difficulties with the WMC and 1.5% for capsule endoscopy. Aspiration has occurred at a rate of approximately 1:1000 in capsule endoscopy studies, which is more common in older patients with reported dysphagia. , Where dysphagia is an issue or the device is too large to be safely ingested, endoscopic insertion using a capsule‐loading device is available to deliver the capsule to the stomach or duodenum. 

Safety practice points for consideration with ingestible devices In general, the safety profiles of the ingestible devices currently commercially available are acceptable with infrequent reporting of serious complications. Ultimately, the nature and magnitude of the risks are dependent on the type of device being used and its indication. The clinician should take into consideration these risks, as outlined in Table . Clearly, some of these clinical scenarios have little to no data upon which the risk can be quantified, but the balance of risk and benefit still has to be evaluated in line with good clinical practice. One particular adverse event is capsule retention, defined as retention of the device within the gastrointestinal tract for 2 weeks or more. Small devices (e.g. less than 11 mm × 26 mm) of low density have minimal risk of retention in a healthy individual and can pass through the narrowest region of the gastrointestinal tract, the pylorus. Reported retention rates vary according to the specific device and its indication for use, ranging from 0.3% for WMC transit assessment and about 2% up to 8.2% in capsule endoscopy for suspected small bowel bleeding and established inflammatory bowel disease, respectively. , Patency capsules, such as the Agile Patency Capsule, as discussed earlier, may be used to assess the risk of retention (measuring 26 mm × 11 mm). Whether the patency capsule used needs to be an exact replica of the intended test device in terms of size and density, or whether a similar device can be used, is uncertain. Capsule retention management may be simply observational in nature or require endoscopic or surgical retrieval, which will be determined by the location of the retained capsule and whether the patient is symptomatic. Problems associated with swallowing devices have been reported uncommonly. For example, post‐marketing studies report a rate of 0.6% for swallowing difficulties with the WMC and 1.5% for capsule endoscopy. Aspiration has occurred at a rate of approximately 1:1000 in capsule endoscopy studies, which is more common in older patients with reported dysphagia. , Where dysphagia is an issue or the device is too large to be safely ingested, endoscopic insertion using a capsule‐loading device is available to deliver the capsule to the stomach or duodenum. 

CONCLUSION: THE FUTURE OF INGESTIBLE ELECTRONIC DEVICES IN GASTROENTEROLOGY That ingestible devices have a place in gastroenterological practice is not in question—capsule endoscopy is viable and technology‐driven, and, in many ways, has revolutionised imaging of the small bowel. Newer technological advances will undoubtedly continue to expand the role of ingestible electronic device technology in gastroenterology. Enhanced optics and sensing will increase diagnostic capabilities and indications for use, and it is highly likely that refinements and additions to the list of interventional capabilities of the capsule means that its role in therapy will also increase in the future, with multimodal devices likely to be developed, ultimately under robotic control. Beyond the scope of this review but worthy of mention is the role artificial intelligence will play in this sphere, particularly with regard to machine learning and computer‐aided diagnoses. While still in relative infancy, the role of ingestible devices in gastroenterology is exciting and provides an opportunity to greatly expand our understanding of gastrointestinal physiology and indeed pathophysiology in a relatively undisturbed and minimally invasive way. It also provides a tool by which changes that may occur in response to pharmacological, dietary or other health interventions over time can be monitored. Studies programmed for each individual's unique clinical circumstances, with assessment and delivery of treatments or substrates promise to herald a new era of personalised medicine. 

Phoebe A. Thwaites: Conceptualization; writing – original draft; writing – review and editing. Chu K. Yao: Writing – review and editing. Emma P. Halmos: Writing – review and editing. Jane G. Muir: Writing – review and editing. Rebecca E. Burgell: Writing – review and editing. Kyle J. Berean: Writing – review and editing. Kourosh Kalantar‐zadeh: Conceptualization; writing – review and editing. Peter R. Gibson: Conceptualization; writing – review and editing. 

PAT is a recipient of an NHMRC postgraduate scholarship. 

Phoebe A. Thwaites: None to declare. Chu K. Yao: Recipient of Atmo Biosciences research support. Emma P. Halmos: Received research grants for investigator‐driven studies from Mindset Health, and speaker honoraria from Sandoz Pty Ltd and Mindset Health. Jane G. Muir: Her department financially benefits from the sale of digital application and booklets on the FODMAP diet. Rebecca E. Burgell: Consultant or advisory board member for Allergan, Atmo Biosciences, Antara. She has received speaking honoraria from Bayer. Kyle J. Berean: Employee and shareholder of Atmo Biosciences. Kourosh Kalantar‐zadeh: Has consulted for Atmo Biosciences. Peter R. Gibson: Consultant or advisory board member for Anatara, Atmo Biosciences, Immunic Therapeutics, Novoviah, Intrinsic Medicine, Topas and Comvita. He has received research grants for investigator‐driven studies from Atmo Biosciences and Mindset Health, and speaker honoraria from Dr Falk Pharma and Mindset Health. He holds shares in Atmo Biosciences. His department financially benefits from the sale of digital application and booklets on the FODMAP diet. 

